STOCK TITAN
  1. Home
  2. Sec-filings
  3. ITRM
  4. [PRE 14A] Iterum Therapeutics plc Ordinary Share Preliminary Proxy Statement

[PRE 14A] Iterum Therapeutics plc Ordinary Share Preliminary Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PRE 14A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ITRM logo
Iterum Therapeutics Plc

NASDAQ:ITRM

ITRM Rankings

#7635 Ranked by Market Cap
N/A Ranked by Dividends

ITRM Latest News

Jul 2, 2025
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2025
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Jun 25, 2025
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Jun 11, 2025
Iterum Therapeutics Announces Partnership for Commercialization Services
May 19, 2025
Iterum Therapeutics Announces Extension of Term of Promissory Note

ITRM Latest SEC Filings

Jul 18, 2025
[8-K] Iterum Therapeutics plc Ordinary Share Reports Material Event
Jul 3, 2025
[Form 4] Iterum Therapeutics plc Ordinary Share Insider Trading Activity
Jul 3, 2025
[Form 3] Iterum Therapeutics plc Ordinary Share Initial Statement of Beneficial Ownership

ITRM Stock Data

43.20M
39.59M
1.19%
8.53%
4.58%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 1